Enzalutamide versus Docetaxel in advanced prostate cancers ( tablets vs injections )

Data presented just now at the American Society of Clinical Oncology meeting at Chicago shows that the Enzalutamide ( Xtandi) tablets improve survival in advanced prostate cancer patients.

So in addition to starting hormone injections to suppress production of testosterone hormones , additional treatment with Enzalutamide ( Xtandi) helps in controlling cancer much more longer.

What’s the downside: The tablets do have physical side effects such as fatigue and it needs to be taken continuously. Since it is a oral medication, in some countries patients do end up paying a lot ( co-pays).

Furthermore, the benefits of Enzalutamide ( Xtandi) is limited to patients who didn’t receive intravenous docetaxel chemotherapy.

Having six doses of chemotherapy over 18 weeks seems to provide the same benefits as 36+ months of Enzalutamide ( Xtandi) .

Other agents are also available in this setting.

So patients need a detailed discussion with their oncologists !!!

Reference

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

Disclaimer: Please note- This blog is NOT medical advice. This blog is purely for information only. See your own doctor to discuss concerns and options relevant for you.